L
Larimar Therapeutics D
D
LRMR
8.33000
USD
-0.07
(-0.83%)
مغلق
حجم التداول
13,489
الربح لكل سهم
0
العائد الربحي
0
P/E
-7
حجم السوق
494,948,013
العنوان: Larimar Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.